Charleston, SC -- (SBWIRE) -- 10/04/2013 -- ImpressivePennyStocks.com covers several stocks on the NASDAQ and New York Stock Exchange that technically qualify as penny stocks, we typically find ones that are on the OTC Market. ImpressivePennyStocks.com issues a special report on the following stocks: Aastrom Biosciences Inc (NASDAQ:ASTM), Golden Star Resources Ltd. (USA) (NYSEMKT:GSS), Mast Therapeutics Inc (NYSEMKT:MSTX), Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN).
Aastrom Biosciences Inc (NASDAQ:ASTM) ended its recent business day with the loss of -1.79% and closed at the price of $0.280 after opening at $0.29. The stock traded during its last trading session with the total volume of 2.71 million shares, as compared to its average volume of 1.20 million shares. Aastrom Biosciences, Inc., a development stage company, engages in the development of patient-specific, cell products for use in the treatment of severe, chronic ischemic cardiovascular diseases.
Has ASTM Found The Bottom and Ready To Move Up? Find Out Here
Golden Star Resources Ltd. (USA) (NYSEMKT:GSS) remained among the day advancers and traded with volume of 6.81 million shares in the last session, as compared to average volume of 3.92 million shares. In comparison with 52 week range of $0.39 - $2.11, it faced lowest price of $0.40 during the last trading session whereas its day highest price was $0.46. The company’s total market capitalization is $117.89 billion, along with 259.11 million shares outstanding. Golden Star Resources Ltd. engages in the acquisition, exploration, development, and operation of gold properties.
For How Long GSS’s Gloss will Attract Investors? Find out via this report
Mast Therapeutics Inc (NYSEMKT:MSTX) showed 11.65 million shares in volume during the last trading session, while the average trading volume remained 908,170.00 shares. The stock kicked off its trading session at $0.52 and closed at $0.490 after mounting 8.50%. Mast Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for serious or life-threatening diseases. Its lead product candidate includes MST-188, a product candidate that has hemorheologic, cytoprotective, and anti-inflammatory properties, which is in phase 3 study for the treatment of sickle cell disease in patients.
Will MSTX Continue To Move Higher? Find Out Here
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock traded during its last trading session with the total traded volume of 44.40 million shares versus its average volume of 938,004.00 shares. The company opened its trade at the price of $0.50 and its closing price was $0.505 after gaining 5.21% for the day. Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system disorders, sexual dysfunction, and other medical needs.
Why Should Investors Buy RNN After The Recent Gain? Just Go Here and Find Out
About Impressive Penny Stocks
We are different here at Impressive Penny Stocks because we care about our subscribers. You can email us any time with questions, tips, or just to say hello. We are real people and we love to hear from our loyal subscribers.
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list.
Never invest into a stock discussed on this web site or the ImpressivePennyStocks.com newsletter unless you can afford to lose your entire investment. Please consult with a certified financial advisor before making any investment decisions.
ImpressivePennyStocks.com is owned and operated by FlipVentures LLC. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. ImpressivePennyStocks’s sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by ImpressivePennyStocks or an offer or solicitation to buy or sell any security. Neither the owner of ImpressivePennyStocks nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. ImpressivePennyStocks makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors.
Read Full Disclaimer at: http://impressivepennystocks.com/disclaimer/#navigation
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)